First program from the Topas platform to enter clinical testing PM203 is one of several proprietary programs being developed by Topas Pemphigus vulgaris is an orphan indication that currently has no cure Topas Therapeutics GmbH (Topas), a Hamburg, Germany-based private platform company leveraging the natural…
To accelerate development of molecular targeted systemic radiotherapy (SR, PRRT) based on its clinical stage technology Edinburgh, United Kingdom – Edinburgh Molecular Imaging Ltd (EMI), a company developing theragnostic agents targeting cancer, today announces the closing of a £3.1 million financing, which will be used to advance…
Epidarex’s therapeutic discovery engine will identify innovative early stage assets, providing hands-on scientific support and funding to drive drug discovery projects Exeed will mould and de-risk opportunities, making them ready for company creation and Series A investment Co-founder Dr. Henning Steinhagen appointed as CEO …
18 month project in collaboration with University of Leeds and Medicines Discovery Catapult will deliver a new compound for treatment of thrombosis Currently available anticoagulants carry high risk of bleeding Leeds, UK, 02 December 2019: LUNAC Therapeutics (LUNAC), a UK based drug discovery company focused…
Novel anticoagulants to minimise bleeding risk by targeting activated Factor XII Builds on a decade of academic research into Factor XII Investment round led by Epidarex Capital and University of Leeds Leeds, UK, 14 November 2019: LUNAC Therapeutics (LUNAC), a UK based drug discovery…
Support for clinical development up to end of Phase 2 for ETD002, first-in-class TMEM16A potentiator for the treatment of all cystic fibrosis patients Milestone Funding through Cystic Fibrosis Foundation’s Therapeutics Development Award programme Brighton, UK, 15 October 2019: Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company…
CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through the inhibition of the complement system, today announced details about its Phase 2 FILLY study investigating intravitreal (IVT) APL-2 (pegcetacoplan)…
Please click here to view the event’s agenda.
CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) announced today the dosing of the first patient in the Phase 3 clinical study PRINCE (APL2-308), evaluating the efficacy and safety of APL-2 for treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH). PRINCE is the second Phase…
LifeArc, a UK-based medical research charity, announced today it is investing £1.5million into Caldan Therapeutics Limited, a company developing novel therapeutics for the treatment of metabolic diseases based on original work. Focusing on activators of free fatty acid receptors (GPR120) implicated in the development of…